Gonadotropinomas

Seminars in Reproductive Medicine

Volumn 20, Issue 4, 2002, Pages 339-348

  Chaidarun, Sushela S ^a   Klibanski, Anne ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinically nonfunctioning tumor; Gonadotrope adenoma; Gonadotropins; Null cell adenoma

Indexed keywords

DOPAMINE DERIVATIVE; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GROWTH FACTOR; HORMONE RECEPTOR; HYPOPHYSIS HORMONE; LUTEINIZING HORMONE; PROTON; SOMATOSTATIN DERIVATIVE;

CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CULTURE; CLINICAL FEATURE; ELECTRON MICROSCOPY; GENE EXPRESSION; GENE THERAPY; GONADOTROPH ADENOMA; HEADACHE; HORMONE DETERMINATION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; ONCOGENE; OVARY HYPERSTIMULATION; PATHOGENESIS; PRECOCIOUS PUBERTY; PREVALENCE; PROTON RADIATION; RADIOSURGERY; REVIEW; SURGICAL TECHNIQUE; TESTIS DISEASE; TUMOR VOLUME; VISUAL FIELD; VISUAL IMPAIRMENT;

ADENOMA; GONADOTROPINS, PITUITARY; HUMANS; PITUITARY NEOPLASMS; PREVALENCE;

EID: 0036869863     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36708     Document Type: Review

References (88)

1. Klibanski A. Nonsecreting pituitary tumors. Endocrinol Metab Clin North Am 1987;16:793-804
2. Greenman Y, Melmed S. Diagnosis and management of nonfunctioning pituitary tumors. Annu Rev Med 1996;47:95-106
3. Snyder PJ. Gonadotroph and other clinically nonfunctioning pituitary adenomas. Cancer Treat Res 1997;89:57-72
4. Samuels MH, Ridgway EC. Glycoprotein-secreting pituitary adenomas. Baillieres Clin Endocrinol Metab 1995;9:337-358
5. Asa SL, Gerrie BM, Singer W, et al. Gonadotropin secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab 1986;62:1011-1019
6. Yamada S, Asa SL, Kovacs K, Muller P, Smyth HS. Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay. J Clin Endocrinol Metab 1989;68:73-80
7. Jameson JL, Klibanski A, Black PM, et al. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. J Clin Invest 1987;80:1472-1478
8. Daneshdoost L, Gennarelli TA, Bashey HM, et al. Recognition of gonadotroph adenomas in women. N Engl J Med 1991;324:589-594
9. Kane LA, Leinung MC, Scheithauer BW, et al. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 1994;79:1135-1140
10. Klibanski A, Deutsch PJ, Jameson JL, et al. Luteinizing hormone-secreting pituitary tumor: Biosynthetic characterization and clinical studies. J Clin Endocrinol Metab 1987;64:536-542
11. Hansen KA, Tho SP, Gomez F, McDonough PG. Nonfunctioning pituitary macroadenoma presenting with mild hyperprolactinemia and amenorrhea. Fertil Steril 1999;72:663-665
12. Christin-Maitre S, Rongieres-Bertrand C, Kottler ML, et al. A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. J Clin Endocrinol Metab 1998;83:3450-3453
13. Djerassi A, Coutifaris C, West VA, et al. Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab 1995;80:591-594
14. Shimon I, Rubinek T, Bar-Hava I, et al. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 2001;86:3635-3640
15. Tashiro H, Katabuchi H, Ohtake H, et al. A follicle-stimulating hormone-secreting gonadotroph adenoma with ovarian enlargement in a 10-year-old girl. Fertil Steril 1999;72:158-160
16. Valimaki MJ, Tiitinen A, Alfthan H, et al. Ovarian hyperstimulation caused by gonadotroph adenoma secreting follicle-stimulating hormone in 28-year-old woman. J Clin Endocrinol Metab 1999;84:4204-4208
17. Ambrosi B, Bassetti M, Ferrario R, et al. Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: Hormonal and immunocytochemical studies. Acta Endocrinol (Copenh) 1990;122:569-576
18. Faggiano M, Criscuolo T, Perrone L, Quarto C, Sinisi AA. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinol (Copenh) 1983;102:167-172
19. Kleinschmidt-DeMasters BK, Lillehei KO. Pathological correlates of pituitary adenomas presenting with apoplexy. Hum Pathol 1998;29:1255-1265
20. Cook DM, Watkins S, Snyder PJ. Gonadotrophin-secreting pituitary adenomas masquerading as primary ovarian failure. Clin Endocrinol (Oxf) 1986;25:729-738
21. Kwekkeboom DJ, de Jong FH, Lamberts SW. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: Relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine. J Clin Endocrinol Metab 1989; 68:1128-1135
22. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas. J Clin Endocrinol Metab 1993;77:784-789
23. Somjen D, Tordjman K, Kohen F, et al. Combined beta FSH and beta LH response to TRH in patients with clinically nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 1997;46:555-562
24. Daneshdoost L, Gennarelli TA, Bashey HM, et al. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:1352-1355
25. Nichols DA, Laws ER Jr, Houser OW, Abboud CE Comparison of magnetic resonance imaging and computed tomography in the preoperative evaluation of pituitary adenomas. Neurosurgery 1988;22:380-385
26. Ho DM, Hsu CY, Ting LT, Chiang H. The clinicopathological characteristics of gonadotroph cell adenoma: A study of 118 cases. Hum Pathol 1997;28:905-911
27. Horvath E, Kovacs K. Gonadotroph adenomas of the human pituitary - Sex-related fine-structural dichotomy: A histologic, immunocytochemical, and electron-microscopic study of 30 tumors. Am J Pathol 1984;117:429-440
28. Kontogeorgos G, Horvath E, Kovacs K. Sex-linked ultrastructural dichotomy of gonadotroph adenomas of the human pituitary: An electron microscopic analysis of 145 tumors. Ultrastruct Pathol 1990;14:475-482
29. Saccomanno K, Bassetti M, Lania A, et al. Immunodetection of glycoprotein hormone subunits in nonfunctioning and glycoprotein hormone-secreting pituitary adenomas. J Endocrinol Invest 1997;20:59-64
30. Aylwin SJ, Welch JP, Davey CL, et al. The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas. J Clin Endocrinol Metab 2001;86:2476-2483
31. Ikuyama S, Ohe K, Sakai Y, et al. Follicle stimulating hormone-beta subunit gene is expressed in parallel with a transcription factor Ad4BP/SF-1 in human pituitary adenomas. Clin Endocrinol (Oxf) 1996;45:187-193
32. McDermott MT, Haugen BR, Gordon DF, et al. Reverse transcription polymerase chain reaction analysis of pituitary hormone, Pit-1 and steroidogenic factor-1 messenger RNA expression in pituitary tumors. Pituitary 1999;2:217-224
33. Asa SL, Cheng Z, Ramyar L, et al. Human pituitary null cell adenomas and oncocytomas in vitro: Effects of adenohypophysiotropic hormones and gonadal steroids on hormone secretion and tumor cell morphology. J Clin Endocrinol Metab 1992;74:1128-1134
34. Alexander JM, Biller BM, Bikkal H, et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990;86:336-340
35. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427-1433
36. Melmed S. Pathogenesis of pituitary tumors. Endocrinol Metab Clin North Am 1999;28:1-12
37. Farrell WE, Clayton RN. Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 2000;21:174-198
38. Spada A, Lania A, Ballare E. G protein abnormalities in pituitary adenomas. Mol Cell Endocrinol 1998;142:1-14
39. Heaney AP, Melmed S. New pituitary oncogenes. Endocr Relat Cancer 2000;7:3-15
40. Zhang X, Horwitz GA, Prezant TR, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1999;13:156-166
41. Seemann N, Kuhn D, Wrocklage C, et al. CDKN2A/p16 inactivation is related to pituitary adenoma type and size. J Pathol 2001;193:491-497
42. Takeuchi S, Koeffler HP, Hinton DR, et al. Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J Endocrinol 1998;157:337-341
43. Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761-767
44. Atkin SL, Jeffreys RV, Foy PM, et al. Effects of basic fibroblastic growth factor on the function and proliferation of human clinically non-functional pituitary adenomas which secreted glycoprotein hormones in vitro. J Endocrinol 1995;144:173-178
45. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 1999;5:1317-1321
46. Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S. Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab 2001;86:867-874
47. Alexander JM, Klibanski A. Gonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro. J Clin Invest 1994;93:2332-2339
48. Chaidarun SS, Klibanski A, Alexander JM. Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. J Clin Endocrinol Metab 1997;82:1058-1065
49. D'Abronzo FH, Swearingen B, Klibanski A, Alexander JM. Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors. J Clin Endocrinol Metab 1999;84:1716-1721
50. Chanson P, De Roux N, Young J, et al. Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas. Eur J Endocrinol 1998;139:157-160
51. Miller GM, Alexander JM, Klibanski A. Gonadotropin-releasing hormone messenger RNA expression in gonadotroph tumors and normal human pituitary. J Clin Endocrinol Metab 1996;81:80-83
52. Alexander JM, Bikkal HA, Zervas NT, Laws ER Jr, Klibanski A. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas. J Clin Endocrinol Metab 1996;81:783-790
53. Chaidarun SS, Eggo MC, Sheppard MC, Stewart PM. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 1994;135:2012-2021
54. Penabad JL, Bashey HM, Asa SL, et al. Decreased follistatin gene expression in gonadotroph adenomas. J Clin Endocrinol Metab 1996;81:3397-3403
55. Chaidarun SS, Eggo MC, Stewart PM, Barber PC, Sheppard MC. Role of growth factors and estrogen as modulators of growth, differentiation, and expression of gonadotropin subunit genes in primary cultured sheep pituitary cells. Endocrinology 1994;134:935-944
56. Spady TJ, Harvell DM, Snyder MC, et al. Estrogen-induced tumorigenesis in the Copenhagen rat: Disparate susceptibilities to development of prolactin-producing pituitary tumors and mammary carcinomas. Cancer Lett 1998;124:95-103
57. Webb P, Nguyen P, Valentine C, et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999;13:1672-1685
58. Kato S. Estrogen receptor-mediated cross-talk with growth factor signaling pathways. Breast Cancer 2001;8:3-9
59. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000;2:335-344
60. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001;81:1535-1565
61. Chaidarun S, Alexander J. Pituitary tumor-specific estrogen receptor splice variants constitutively activate c-fos gene expression and increase cellular proliferation. The Tenth International Congress of Endocrinology, 1997;OR9-1:75
62. Chaidarun SS, Alexander JM. A tumor-specific truncated estrogen receptor splice variant enhances estrogen-stimulated gene expression. Mol Endocrinol 1998;12:1355-1366
63. Chaidarun SS, Swearingen B, Alexander JM. Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: Functional interactions with ER alpha and a tumor-specific splice variant. J Clin Endocrinol Metab 1998; 83:3308-3315
64. Ying SY. Inhibins, activins and follistatins. J Steroid Biochem 1989;33:705-713
65. Knight PG. Roles of inhibins, activins, and follistatin in the female reproductive system. Front Neuroendocrinol 1996;17:476-509
66. Blumenfeld Z, Ritter M. Inhibin, activin, and follistatin in human fetal pituitary and gonadal physiology. Ann N Y Acad Sci 2001;943:34-48
67. Danila DC, Inder WJ, Zhang X, et al. Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Metab 2000;85:1009-1015
68. Zhou Y, Sun H, Danila DC, et al. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Mol Endocrinol 2000;14:2066-2075
69. Pellegrini-Bouiller I, Manrique C, Gunz G, et al. Expression of the members of the Ptx family of transcription factors in human pituitary adenomas. J Clin Endocrinol Metab 1999; 84:2212-2220
70. Skelly RH, Korbonits M, Grossman A, et al. Expression of the pituitary transcription factor Ptx-1, but not that of the transactivating factor prop-1, is reduced in human corticotroph adenomas and is associated with decreased alpha-subunit secretion. J Clin Endocrinol Metab 2000;85:2537-2542
71. Achermann JC, Weiss J, Lee EJ, Jameson JL. Inherited disorders of the gonadotropin hormones. Mol Cell Endocrinol 2001;179:89-96
72. Laws ER Jr, Thapar K. Pituitary surgery. Endocrinol Metab Clin North Am 1999;28:119-131
73. Black PM, Zervas NT, Candia G. Management of large pituitary adenomas by transsphenoidal surgery. Surg Neurol 1988;29:443-447
74. Tsang RW, Laperriere NJ, Simpson WJ, et al. Glioma arising after radiation therapy for pituitary adenoma: A report of four patients and estimation of risk. Cancer 1993;72:2227-2233
75. Izawa M, Hayashi M, Nakaya K, et al. Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 2000;93(suppl 3):19-22
76. Pollock BE, Gorman DA, Schomberg PJ, Kline RW. The Mayo Clinic gamma knife experience: Indications and initial results. Mayo Clin Proc 1999;74:5-13
77. Yamamoto M. Gamma knife radiosurgery: Technology, applications, and future directions. Neurosurg Clin N Am 1999; 10:181-202
78. Sims E, Doughty D, Macaulay E, et al. Stereotactically delivered cranial radiation therapy: A ten-year experience of linac-based radiosurgery in the UK. Clin Oncol (R Coll Radiol) 1999;11:303-320
79. Mitsumori M, Shrieve DC, Alexander E III, et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1998;42:573-580
80. Raju MR. Proton radiobiology, radiosurgery and radiotherapy. Int J Radiat Biol 1995;67:237-259
81. Levy RP, Fabrikant JI, Frankel KA, et al. Heavy-charged-particle radiosurgery of the pituitary gland: Clinical results of 840 patients. Stereotact Funct Neurosurg 1991;57:22-35
82. Pai HH, Thornton A, Katznelson L, et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: Demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;49:1079-1092
83. Rocher FP, Sentenac I, Berger C, et al. Stereotactic radiosurgery: The Lyon experience. Acta Neurochir Suppl (Wien) 1995;63:109-114
84. Shomali ME, Katznelson L. Medical therapy for gonadotroph and thyrotroph tumors. Endocrinol Metab Clin North Am 1999;28:223-240
85. Sassolas G, Trouillas J, Treluyer C, Perrin G. Management of nonfunctioning pituitary adenomas. Acta Endocrinol (Copenh) 1993;129(suppl 1):21-26
86. Hofland LJ, de Herder WW, Waaijers M, et al. Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. J Clin Endocrinol Metab 1999;84:3336-3343
87. Lee EJ, Anderson LM, Thimmapaya B, Jameson JL. Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J Clin Endocrinol Metab 1999;84:786-794
88. Lee EJ, Thimmapaya B, Jameson JL. Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: Implications for gene therapy. Neurosurgery 2000;46:1461-1468; discussion 1468-1469